The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...

Neha Anand, Analyst, Biopharma Intelligence Services, Citeline, explains how positive Phase III results for Emrelis may position AbbVie as a key player in MET-high non-small cell lung cancer, ...

The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives and advance five ...

AstraZeneca ’s AZN second-quarter 2025 core earnings of $1.09 per American depositary share (ADS) came in line with the Zacks ...

Antibody-drug conjugates are a growing class of biopharmaceuticals that combine the precision of monoclonal antibodies with ...

Be hugged by an artificial 'muscle' in Japanese 'well-down' popup which involves relaxing into your natural self ...

Eli Lilly LLY offers a diverse range of products that serve multiple therapeutic areas. While the company’s primary focus is ...

Researchers who conducted a real-world analysis of trastuzumab deruxtecan found the drug to be effective in treating metastatic breast cancer, though survival outcomes did not reach clinical trial ...